As of 2024-12-12, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 16.9x | 15.0x |
| Forward P/E multiples | 15.8x - 20.1x | 16.3x |
| Fair Price | (60.58) - (65.45) | (60.02) |
| Upside | -133.9% - -136.6% | -133.6% |
| Date | EV/EBITDA |